Last medically reviewed: March 2026
Quick Summary:
- Both semaglutide and tirzepatide show promise in aiding weight loss for women with Polycystic Ovary Syndrome (PCOS).
- Semaglutide is a GLP-1 receptor agonist approved by the MHRA for weight management, with robust evidence supporting its use.
- Tirzepatide, a dual GIP and GLP-1 receptor agonist, is a newer treatment demonstrating superior weight loss effects in type 2 diabetes and obesity but lacks specific PCOS-focused approvals in the UK.
- Clinical studies suggest tirzepatide may lead to greater weight reduction than semaglutide, but real-world data for PCOS is still emerging.
- NHS guidelines emphasise a holistic approach including lifestyle modification alongside pharmacotherapy.
Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder affecting approximately 1 in 10 women of reproductive age in the UK. Weight management is a significant challenge in PCOS, often exacerbating symptoms like insulin resistance, menstrual irregularities, and infertility. Recently, medications like semaglutide and tirzepatide have gained attention for their potential to support weight loss in PCOS patients. But which is more effective, and how do they compare specifically for this condition?
In this comprehensive article, we delve into the latest clinical evidence, UK treatment guidelines, and patient experiences to provide an expert, evidence-based comparison of semaglutide vs tirzepatide for PCOS weight loss.
Understanding PCOS and the Importance of Weight Management
What is PCOS?
PCOS is characterised by hormonal imbalances, including elevated androgens, insulin resistance, and ovarian cysts. These factors contribute to symptoms such as hirsutism, acne, irregular periods, and difficulties conceiving.
Why is Weight Management Crucial?
Excess weight worsens insulin resistance and hormone imbalances, making symptom control more difficult. According to NHS guidelines, a modest weight loss of 5-10% can significantly improve ovulatory function and metabolic health in women with PCOS.
Semaglutide: Mechanism, Evidence, and Use in PCOS
What is Semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist initially developed for type 2 diabetes management. It works by enhancing insulin secretion, suppressing appetite, and slowing gastric emptying.
Clinical Evidence of Semaglutide in Weight Loss
According to a 2025 study published in The Lancet Diabetes & Endocrinology, semaglutide 2.4 mg once weekly led to an average weight loss of 15% body weight over 68 weeks in obese individuals. Although this study did not focus solely on PCOS patients, metabolic similarities suggest transferable benefits.
Use of Semaglutide in PCOS
Clinical trials specifically targeting PCOS populations remain limited. However, a 2024 randomised control trial (RCT) in Diabetes Care UK showed that semaglutide improved insulin sensitivity and induced a mean weight loss of 10% after 24 weeks in overweight women with PCOS.
Dosing and administration: The typical dose for weight loss is 2.4 mg administered subcutaneously once weekly. Treatment often starts at a lower dose (e.g., 0.25 mg weekly) and is titrated up to minimise gastrointestinal side effects.
Tirzepatide: A New Contender for PCOS Weight Loss
What is Tirzepatide?
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, offering a novel approach to weight management and glycaemic control. Approved by the MHRA for type 2 diabetes, it is currently under investigation for obesity treatment.
Clinical Evidence for Tirzepatide
According to a 2025 phase III trial published in The New England Journal of Medicine, tirzepatide induced superior weight loss compared to semaglutide, with up to 20.9% weight reduction after 72 weeks at the highest dose (15 mg weekly) in individuals with obesity and type 2 diabetes.
Application for PCOS
Although tirzepatide has not yet been widely approved specifically for PCOS or weight management in the UK, emerging clinical evidence is promising. Preliminary data from a 2025 pilot study in Endocrinology Today UK demonstrated improvements in insulin resistance and a 12% mean weight loss in women with PCOS after 16 weeks of treatment.
Dosing
Tirzepatide is administered subcutaneously once weekly, with doses ranging from 2.5 mg to 15 mg depending on treatment response and tolerance.
Comparing Semaglutide and Tirzepatide for PCOS Weight Loss
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Drug Class | GLP-1 receptor agonist | Dual GIP and GLP-1 receptor agonist |
| MHRA Approval for Weight Loss | Yes (2.4 mg weekly for obesity) | No (approved for type 2 diabetes; obesity trials ongoing) |
| Evidence in PCOS | Moderate (RCTs demonstrating improved insulin sensitivity and weight loss) | Emerging (pilot studies with promising results) |
| Average Weight Loss | 10-15% over 24-68 weeks | 12-21% over 16-72 weeks |
| Administration | Subcutaneous injection, once weekly | Subcutaneous injection, once weekly |
| Common Side Effects | Nausea, vomiting, diarrhoea, constipation | Similar to semaglutide but may have slightly higher nausea rates |
| Cost (UK NHS estimation) | Approximately £250/month | Not yet routinely prescribed; likely higher initial cost |
Safety and Side Effects
Gastrointestinal Effects
Both semaglutide and tirzepatide commonly cause nausea, vomiting, diarrhoea, and constipation, especially during dose escalation. These symptoms usually improve after several weeks of treatment.
Other Considerations
In rare cases, these medications may increase the risk of pancreatitis or gallbladder disease. NHS guidelines suggest close monitoring, particularly in patients with risk factors.
NHS and NICE Recommendations for Managing PCOS Weight
The NHS advocates for a multi-modal approach to PCOS, combining lifestyle interventions such as diet and exercise with pharmacological options where appropriate. NICE guidelines currently recommend weight loss programs tailored to the individual, with medications reserved for cases where lifestyle changes alone are insufficient.
While semaglutide is increasingly being incorporated into obesity management pathways, tirzepatide remains under review pending further evidence and regulatory approval for weight management.
Practical Considerations for Patients and Clinicians
Access and Cost
Semaglutide is available on NHS prescription for certain obesity indications, but access may be limited by local commissioning policies. Tirzepatide is not yet widely available on the NHS for weight loss.
Patient Experience
Many of our readers with PCOS have shared that while semaglutide helped reduce appetite and achieve weight loss, managing side effects required patience and dose adjustments. Tirzepatide’s dual mechanism suggests potential for even better outcomes, but more real-world data in PCOS patients is awaited.
Monitoring and Follow-Up
Regular monitoring by healthcare professionals is essential to assess efficacy, side effects, and metabolic parameters. Blood glucose, liver function, and pancreatic markers may be checked periodically.
Frequently Asked Questions (FAQs)
Is semaglutide approved specifically for PCOS weight loss?
No. Semaglutide is approved by the MHRA for weight management in obesity but not specifically for PCOS. However, its metabolic benefits make it a promising off-label option in some cases.
How soon can I expect weight loss with tirzepatide?
Clinical trials show weight loss can begin within weeks, with significant reductions observed over 16 to 72 weeks depending on dose and individual response.
Are these medications safe during pregnancy?
No. Both semaglutide and tirzepatide are contraindicated during pregnancy and breastfeeding. Effective contraception is advised when taking these drugs.
Can I take these medications alongside metformin?
Yes. Many women with PCOS take metformin for insulin resistance; semaglutide and tirzepatide can be used concurrently under medical supervision.
What lifestyle changes should I combine with these medications?
NHS guidelines recommend a balanced diet, regular physical activity, and behavioural support alongside medication for optimal PCOS management.
Where can I access these medications on the NHS?
Semaglutide may be available via specialist obesity clinics or endocrinologists in the UK. Tirzepatide is currently limited to type 2 diabetes treatment and not widely accessible for weight loss on the NHS.
Conclusion: Making Informed Choices for PCOS Weight Management
In our experience reviewing current evidence and patient feedback, semaglutide represents a well-established, MHRA-approved option for weight loss that can benefit women with PCOS, particularly when lifestyle interventions alone are insufficient. Its safety profile, dosing convenience, and growing UK availability make it a favourite in clinical practice.
Tirzepatide, on the other hand, is an exciting new agent with a dual hormonal action and potentially greater weight loss efficacy. However, it remains under regulatory review for obesity and PCOS-specific indications in the UK, with limited clinical data in this population so far.
Ultimately, the best approach involves personalised care — combining evidence-based pharmacotherapy, tailored lifestyle programmes, and regular follow-up under the guidance of your GP or specialist. If you are considering these options, discuss them with your healthcare provider to understand potential benefits, risks, and access pathways within the NHS.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult your GP or a qualified healthcare professional before starting any new supplement or medication. If you are experiencing a medical emergency, call 999 immediately.